Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 603168.SS

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 3.75

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Price to Sales Ratio (P/S) is 3.75 on January 14, 2025, a -53.02% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. 52-week high Price to Sales Ratio (P/S) is 7.99 on January 15, 2024, which is 112.86% above the current Price to Sales Ratio (P/S).
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. 52-week low Price to Sales Ratio (P/S) is 3.58 on January 13, 2025, which is -4.61% below the current Price to Sales Ratio (P/S).
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 5.23.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 603168.SS

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.

CEO	Mr. Mingxiong Huang
IPO Date	July 2, 2014
Location	China
Headquarters	No. 1588 Xinming Road
Employees	1,385
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antipyretic and analgesic, antibacterial anti-inflammatory, endocrine, auxiliary, cardiovascular, detoxification, diuretic row stone, gynecology, and infusion categories. It offers its products in injections, oral solutions, eye drops, tablets, capsules, and other dosage forms. Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. was founded in 1978 and is based in Pinghu, China.

Key trends

Past 5 years